Gapping up
In reaction to strong earnings/guidance:
- USAK +24.5%, DATA +16.7%, VIAV +10.1%, SNE +7.2%, ATHN +6.8%, DECK +6.6%, AMZN +6%, S +4.9%, EPAY +4.2%, POST +3.3%, CURO +3.1%, HMC +3.1%, WFT +2.5%, ENVA +2.1%, NFG +2.1%, VLP +1.9%, TICC +1.6%, MSI +1.6%, EL +1.5%, EMN +1.4%, PACB +1.1%, CY +0.9%, EW +0.8%, AAPL +0.8%
Other news:
- ERII +15.3% (indicated higher after providing investor update in presentation )
- MNOV +13.9% (MediciNova to present additional positive clinical data from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis )
- ATOS +7.3% (presents additional findings from its Phase 1 study of Atossa's proprietary oral Endoxifen)
- ADMS +4% (announces results of Phase 2 proof-of-concept clinical trial of ADS-5102in multiple sclerosis patients published online in Multiple Sclerosis Journal)
- GES +3.2% (issues statement responding to allegations involving Executive Chairman and Chief Creative Officer Paul Marciano -- current investigation has not corroborated past allegations)
- PQ +2.9% (PetroQuest Energy announced the sale of its Gulf of Mexico properties; estimates that its 2017 production was approximately 27.6 Bcfe including the sold assets)
- VKTX +2.6% (commences common stock offering; indicated higher on anticipated favorable pricing)
- PGNX +1.8% (ticking higher after announcing presentation of AZEDRA biochemical tumor marker data at Endocrine Society Annual Meeting March 17-20)
- VIAB +1.6% (CBS/Viacom establish special committee to evaluate a potential combination)
- PBYI +0.8% (enters into an exclusive agreement under which CANbridge will develop and commercialize NERLYNX (neratinib) in mainland China, Taiwan, Hong Kong, and Macau), .
Analyst comments:
- APRN +6% (initiated with a Buy at Gabelli & Co)
- VNOM +2.6% (initiated with Buy ratings at Deutsche Bank)
- NOK +1.3% (upgraded to Buy from Neutral at MKM Partners)